tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'CELG'

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Written by ι Stock Market Media Group Staff — May 20, 2013

The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner’s treatment.  Two biotechnology companies are registering impressive data in each of their own pancreatic cancer trials, so impressive in fact, Eli Lilly & Co. (NYSE: LLY) is surely feeling its long time reign as the current standard single-drug treatment for the disease being threatened.  Nuvilex, Inc. (OTCQB: NVLX) and Celgene Corp. (NASDAQ: ...

Read More →
0

Nuvilex, Inc. Pancreatic Cancer Trials Could Make “Cell-in-a-Box” Gold Standard

Nuvilex, Inc. Pancreatic Cancer Trials Could Make “Cell-in-a-Box” Gold Standard

Written by ι Stock Market Media Group Staff — April 29. 2013

While many biotech and pharmaceutical companies are designing one drug after another to address specific problems, Nuvilex, Inc. (OTCQB: NVLX) is using its own living cell encapsulation as a “one size fits all” type solution.  The company is off to a great start at getting its “Cell-in-a-Box” technology on the map with its work in late stage, inoperable pancreatic cancer. 

Nuvilex is headquartered in Silver Spring, Maryland, and while it is a ...

Read More →
0

Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer

Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer

Written by ι Stock Market Media — March 5, 2013

In late January, those with advanced stage pancreatic cancer received some good news when Celgene, Corp (NASDAQ: CELG) announced the results of its large scale phase III trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), held in San Francisco. 

Pancreatic cancer is difficult to diagnose and treat until it is at an advanced stage.  Survival of patients with advanced, inoperable pancreatic cancer ...

Read More →
0

Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity than Competitors

Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity than Competitors

Written by ι Stock Market Media Group Staff — May 2, 2013

Nuvilex, Inc. (OTCQB: NVLX) has already produced impressive results from its two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer.  Two key results pulled from the data of those trials, are that the median survival rate was higher than that of the current gold standard for the disease and better than those of other competitors’ treatments when clinical trial reports are examined.  Furthermore, the overall side-effect profile ...

Read More →
0
Page 4 of 4 1234